JP2022553841A5 - - Google Patents

Info

Publication number
JP2022553841A5
JP2022553841A5 JP2022525957A JP2022525957A JP2022553841A5 JP 2022553841 A5 JP2022553841 A5 JP 2022553841A5 JP 2022525957 A JP2022525957 A JP 2022525957A JP 2022525957 A JP2022525957 A JP 2022525957A JP 2022553841 A5 JP2022553841 A5 JP 2022553841A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
solvate
acceptable salt
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022525957A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553841A (ja
JP7635228B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/059210 external-priority patent/WO2021092246A1/en
Publication of JP2022553841A publication Critical patent/JP2022553841A/ja
Publication of JP2022553841A5 publication Critical patent/JP2022553841A5/ja
Application granted granted Critical
Publication of JP7635228B2 publication Critical patent/JP7635228B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022525957A 2019-11-08 2020-11-05 Tyk2偽キナーゼリガンド Active JP7635228B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962933179P 2019-11-08 2019-11-08
US62/933,179 2019-11-08
US202063046514P 2020-06-30 2020-06-30
US63/046,514 2020-06-30
PCT/US2020/059210 WO2021092246A1 (en) 2019-11-08 2020-11-05 Tyk2 pseudokinase ligands

Publications (3)

Publication Number Publication Date
JP2022553841A JP2022553841A (ja) 2022-12-26
JP2022553841A5 true JP2022553841A5 (enExample) 2023-11-13
JP7635228B2 JP7635228B2 (ja) 2025-02-25

Family

ID=75846491

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022525957A Active JP7635228B2 (ja) 2019-11-08 2020-11-05 Tyk2偽キナーゼリガンド

Country Status (17)

Country Link
US (2) US11753411B2 (enExample)
EP (1) EP4054581A4 (enExample)
JP (1) JP7635228B2 (enExample)
KR (1) KR102938141B1 (enExample)
CN (1) CN114929226B (enExample)
AU (1) AU2020378345A1 (enExample)
BR (1) BR112022008821A2 (enExample)
CA (1) CA3160637A1 (enExample)
CL (1) CL2022001178A1 (enExample)
CO (1) CO2022007814A2 (enExample)
GE (1) GEP20257840B (enExample)
IL (1) IL292785B2 (enExample)
MX (1) MX2022005563A (enExample)
PH (1) PH12022551105A1 (enExample)
TW (1) TWI882032B (enExample)
UA (1) UA129894C2 (enExample)
WO (1) WO2021092246A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20250048T1 (hr) 2018-10-22 2025-03-28 Alumis Inc. Inhibitori tyk2 i njihova uporaba
MX2021009555A (es) * 2019-02-07 2021-10-13 Ventyx Biosciences Inc Ligandos de pseudocinasa tyk2.
IL286248B2 (en) * 2019-03-11 2025-12-01 Alumis Inc Tyk2 inhibitors and uses thereof
EA202192625A1 (ru) 2019-03-26 2022-03-21 Вентикс Байосайенсес, Инк. Лиганды псевдокиназы tyk2
KR102938141B1 (ko) 2019-11-08 2026-03-11 벤틱스 바이오사이언스, 인크. Tyk2 슈도키나제 리간드
CA3167339A1 (en) 2020-01-13 2021-07-22 Verge Analytics, Inc. Substituted pyrazolo-pyrimidines and uses thereof
EP4423086A1 (en) 2021-10-25 2024-09-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
WO2024011136A1 (en) * 2022-07-06 2024-01-11 Ventyx Biosciences, Inc. Crystalline forms of a tyk2 inhibitor
EP4649082A1 (en) * 2023-01-13 2025-11-19 Ventyx Biosciences, Inc. Preparation of a tyk2 inhibitor
CN117247389A (zh) * 2023-09-18 2023-12-19 南京友怡医药科技有限公司 一种靶向药物化合物及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7196078B2 (en) 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7161003B1 (en) 2002-09-04 2007-01-09 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
KR20050115252A (ko) 2003-02-28 2005-12-07 데이진 화-마 가부시키가이샤 피라졸로[1,5-a]피리미딘 유도체
US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
BRPI0616985B1 (pt) * 2005-10-06 2021-10-26 Merck Sharp & Dohme Corp. Composto de pirazolo[1,5-a]pirimidina, e, uso de um composto
US8591943B2 (en) * 2009-04-09 2013-11-26 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors
KR102015402B1 (ko) 2010-05-20 2019-08-28 어레이 바이오파마 인크. Trk 키나제 저해제로서의 매크로시클릭 화합물
TWI744256B (zh) 2015-11-06 2021-11-01 美商英塞特公司 作為PI3K-γ抑制劑之雜環化合物
KR102477063B1 (ko) 2016-10-28 2022-12-12 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 헤테로비시클릭 화합물
TWI868528B (zh) 2017-03-08 2025-01-01 日商武田藥品工業股份有限公司 Tyk2抑制劑之生產方法
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US20200360381A1 (en) 2017-05-15 2020-11-19 Dana-Farber Cancer Institute, Inc. Compounds for treating dengue virus infection and other viral infections
WO2019023468A1 (en) * 2017-07-28 2019-01-31 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
ES2938751T3 (es) 2018-09-10 2023-04-14 Lilly Co Eli Derivados de pirazol[1,5-a]pirimidina-3-carboxamida útiles en el tratamiento de la psoriasis y el lupus eritematoso sistémico
CA3115088A1 (en) 2018-10-15 2020-04-23 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
AR117177A1 (es) 2018-12-10 2021-07-14 Lilly Co Eli DERIVADOS DE 7-(METILAMINO)PIRAZOLO[1,5-A]PIRIMIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE IL-23 E INFa
MX2021009555A (es) 2019-02-07 2021-10-13 Ventyx Biosciences Inc Ligandos de pseudocinasa tyk2.
IL286248B2 (en) 2019-03-11 2025-12-01 Alumis Inc Tyk2 inhibitors and uses thereof
EA202192625A1 (ru) 2019-03-26 2022-03-21 Вентикс Байосайенсес, Инк. Лиганды псевдокиназы tyk2
KR102938141B1 (ko) 2019-11-08 2026-03-11 벤틱스 바이오사이언스, 인크. Tyk2 슈도키나제 리간드

Similar Documents

Publication Publication Date Title
JP2022519696A5 (enExample)
JP2022529311A5 (enExample)
JP2024520481A5 (enExample)
CA2881057C (en) Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
IL292785B2 (en) Tyk2 pseudokinase ligands
JP2021522262A5 (enExample)
JP2021523221A5 (enExample)
JP2022545633A5 (enExample)
JP2018504437A5 (enExample)
JP2022547617A5 (enExample)
JP2019512505A5 (enExample)
JP2022550640A5 (enExample)
HRP20161308T1 (hr) 5-alkinil-pirimidini
JP2015502387A5 (enExample)
JP2015529224A5 (enExample)
JP2020500178A5 (enExample)
RU2010143857A (ru) Тетрагидрофенантридиноны и тетрагидроциклопентахинолиноны в качестве ингибриторов parp и ингибиторов полимеризации тубулина
JP2013525448A5 (enExample)
CA2797533A1 (en) Compounds that modulate intracellular calcium
RU2012142550A (ru) Производные пирролопиразина и их применение в качестве ингибиторов jak и syk
JP2022552445A5 (enExample)
JP2022532877A5 (enExample)
JP2022518523A5 (enExample)
JP2022509206A5 (enExample)
CN109790158A (zh) 作为jak抑制剂杂环化合物,该化合物的盐类及其治疗用途